PARG inhibitor SYX-3759 shows selective and potent in vitro and in vivo cytotoxicity in HRD tumors

May 9, 2023

Data on the poly(ADP-ribose) glycohydrolase (PARG) inhibitor SYX-3759, being investigated for the treatment of homologous recombination deficient (HRD) malignancies, were recently discussed by researchers from Hangzhou Synrx Therapeutics Technology Co. Ltd.

BioWorld Science Conferences New compound Cancer

Today's news in brief

BioWorld

BioWorld briefs for Jan 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 6, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...